|Bid||0.3252 x 3000|
|Ask||0.3273 x 1000|
|Day's Range||0.3180 - 0.3389|
|52 Week Range||0.1800 - 2.9000|
|Beta (3Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.15|
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting. MerTK is emerging as a promising target for cancer immunotherapy. Its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors.
The biotech's spending cuts help it preserve cash to fund ongoing clinical studies that are key to its future success.
Celldex (CLDX) delivered earnings and revenue surprises of 46.67% and -54.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 4 cents. Losses, adjusted for non-recurring gains, were 8 cents per share. The biopharmaceutical company posted revenue ...
HAMPTON, N.J., Nov. 07, 2018 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018. “We.
The clinical-stage biotech received a spark from excitement over the release of abstracts to be presented at a major conference.
Celldex Therapeutics Inc (NASDAQ:CLDX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CLDXRead More...
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...
The clinical-stage biotech sees bottom-line improvement after slashing spending following a big pipeline setback earlier this year.
Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 11 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Celldex Therapeutics, Inc. (NASDAQ: CLDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...